The FINER clinical trial aims to find out if advanced ER-positive/HER2-negative breast cancer will remain under control for longer in patients who are given a new drug, ipatasertib, in addition to the standard treatment, fulvestrant. Ipatasertib works by blocking a cancer cell growth pathway (called PI3K-AKT-mTOR), which has been shown to be involved in some ER-positive breast cancers becoming resistant to treatment.

Who is the trial for? Those whose advanced ER-positive/HER2-negative breast cancer has progressed after ‘first line’ treatment with a CDK 4/6 inhibitor (such as palbociclib (Ibrance)) and an aromatase inhibitor (such as anastrozole, exemestane or letrozole).

Auckland City Hospital and Wellington Hospital are the New Zealand sites for this trial.

You can read more about this trial here and here.

Please consult with your doctor or medical team if you are interested in participating in this trial.

29 April 2024